Table 1.
Characteristics, laboratory findings, and clinical outcomes of participants
| All n = 54 |
|
|---|---|
| Age, yearsa | 9.8 ± 2.4 |
| Male, n (%) | 31 (57.4%) |
| Treatment during a stable state, n (%) | |
| ICS | 6 (11.1%) |
| ICS/LABA | 22 (40.7%) |
| Anti-lgE antibody | 1 (1.9%) |
| Symptom | |
| Wheezes, n (%) | 46 (85.2%) |
| Duration of URTI symptoms before consultation, daysb | 3 (2–6) |
| Body temperature, °Ca | 37.3 ± 0.8 |
| Laboratory findings | |
| CRP, mg/dLb | 0.49 (0.11–1.15) |
| WBC count, /μLa | 8453 ± 2763 |
| Eosinophil count in bloods, /μLb | 130 (11–537) |
| Eosinophil percentage in blood, %b | 1.5 (0.1–6.3) |
| Total serum IgE, IU/mLb | 1050 (595–1891) |
| Hospitalization duration, daysb | 7 (6–8) |
| Treatment with systemic corticosteroids, n (%) | 53 (98.1%) |
| Duration with systemic corticosteroids, daysb | 5 (4–7) |
Data are the mean ± standard deviationa and the median (interquartile range)b
Number of participants with missing data were as follow: 2 for CRP; 1 for WBC count and eosinophil count and percentage in blood, 8 for total serum IgE
ICS inhaled corticosteroids, LABA long-acting beta2-agonist, URTI upper respiratory tract infection, CRP C-reactive protein, WBC white blood cell, IgE immunoglobulin E